Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial

Journal of Clinical Oncology

Volumn 18, Issue 7, 2000, Pages 1399-1411

  Kaufmann, Manfred ^a   Bajetta, Emilio ^a   Dirix, Luc Yves ^a   Fein, Luis Enrique ^a   Jones, Stephen E ^a   Zilembo, Nicoletta ^a   Dugardyn, Jean Louis ^a   Nasurdi, Cristina ^a   Mennel, Robert G ^a   Cervek, Jozica ^a   Fowst, Camilla ^a   Polli, Anna ^a   Di Salle, Enrico ^a   Arkhipov, Alexei ^a   Piscitelli, Gabriella ^a   Miller, Langdon L ^a   Massimini, Giorgio ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; MEGESTROL ACETATE; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL TIME; TREATMENT FAILURE; VERTIGO; VOMITING;

EID: 0034128928     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.7.1399     Document Type: Article

References (31)

1. Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207-214, 1973
2. Brodie AMH, Njar VCO: Aromatase inhibitors and breast cancer. Semin Oncol 23:10-20, 1996 (suppl 9)
3. Harvey HA: Aromatase inhibitors in clinical practice: Current status and a look to the future. Semin Oncol 23:33-38, 1996 (suppl 9)
4. Honig SF: Treatment of metastatic disease, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven, 1996, pp 669-734
5. Thürlimann B, Castiglione M, Hsu-Schmitz SF, et al: Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 33:1017-1024, 1997
6. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
7. Buzdar AU, Jonat W, Howell A, et al: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83:1142-1152, 1998
8. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase II trials. J Clin Oncol 14:2000-2011, 1996
9. Miller WR: Aromatase inhibitors. Endocr-Relat Cancer 3:65-79, 1996
10. di Salle E, Giudici D, Briatico G, et al: Novel irreversible aromatase inhibitors. Ann N Y Acad Sci 595:357-367, 1990
11. di Salle E, Briatico G, Giudici D, et al: Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol 49:289-294, 1994
12. Geisler J, Johannessen DC, Anker G, et al: Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. Eur J Cancer 32A:789-792, 1996
13. Murray R, Pitt P: Aromatase inhibition with 4-OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 35:249-253, 1995
14. Johannessen DC, Engan T, di Salle E, et al: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3:1101-1108, 1997
15. Jones S, Belt R, Cooper B, et al: A phase II study of antitumor efficacy and safety of exemestane (EXE) as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refractory to tamoxifen (Tam). Breast Cancer Res Treat 50:304, 1998 (abstr 436)
16. Kvinnsland S, Anker G, Dirix LY, et al: Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postmenopausal breast cancer patients (MBC) failing tamoxifen (TAM). Eur J Cancer 34:S91, 1998 (suppl 5, abstr 408)
17. Thürlimann B, Paridaens R, Serin D, et al: Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study. Eur J Cancer 33:1767-1773, 1997
18. Lønning PE, Bajetta E, Murray R, et al: A phase II study of exemestane (EXE) in metastatic breast cancer (MBC) patients failing non steroidal aromatase inhibitors (ns-Als). Breast Cancer Res Treat 50:304, 1998 (abstr 435)
19. Jones C, Vogel L, Fehrenbacher P, et al: Antitumor efficacy of exemestane (Nikidess, EXE) as third-line hormonal therapy in the treatment of postmenopausal women with metastatic breast cancer refractory to tamoxifen and Megace. Proc Am Soc Clin Oncol 17:150a, 1998 (abstr 573)
20. Jones S, Chang A, Lusch C, et al: A phase II confirmatory study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients (pts) with metastatic breast cancer (MBC) refractory to tamoxifen (Tam) and Megace. Breast Cancer Res Treat 50:304, 1998 (abstr 437)
21. Paridaens R, Thomas J, Wildiers J, et al: Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: A phase I study. Anticancer Drugs 9:675-683, 1998
22. Zilembo N, Noberasco C, Bajetta E, et al: Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 72:1007-1012, 1995
23. Bajetta E, Zilembo N, Noberasco C, et al: The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur J Cancer 33:587-591,1997
24. di Salle E, Ornati G, Paridaens R, et al: Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304), in Motta M, Serio E (eds): Sex Hormone and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam, the Netherlands, Elsevier Science B.V., 1994, pp 303-310
25. Purohit OP, Anthony C, Radstone CR, et al: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70:554-558, 1994
26. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
27. Snedecor GW: Statistical Methods. Ames, IA, Iowa State University Press, 1964:85-101
28. Huitson A: The Analysis of Variance. London, United Kingdom, C. Griffin, 1966
29. Tedeschi M, Kvinnstad S, Jones SE, et al: Hormonal therapy in breast cancer and predominant visceral disease: Effectiveness of the new oral aromatase inactivator, Aromasin (exemestane) in advanced breast cancer patients having progressed on antiestrogens. Eur J Cancer 5:S316, 1999 (suppl 4, abstr 1270)
30. Robertson JFR, Lee D, on behalf of the Arimidex Study Group: Static disease (no change) is an important remission criteria in patients treated with the aromatase inhibitor anastrozole. Proc Am Soc Clin Oncol 16:151a, 1997 (abstr 528)
31. Lundgren S, Helle SI, Lonning PE: Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 2:1515-1521, 1996